Oncology Supportive Care · LP-166
Mesna Injection
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-166Oncology Supportive Care
- Generic identity
- MesnaInjection
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-166
- Generic ingredient
- Mesna
- Dosage form
- Injection
- Proposed strength
- 100 mg/mL
- Proposed pack
- Ampoule 4 mL / 10 mL
- Portfolio category
- Oncology Supportive Care
About Mesna
Mesna is a uroprotective medicine used with specific cytotoxic treatments to reduce the risk of bladder injury from harmful metabolites. It is supportive therapy rather than an anticancer medicine in its own right. Its place in care is tied to the accompanying treatment and the clinical protocol. Mesna does not eliminate the need for monitoring or protect against every adverse effect of chemotherapy.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Ifosfamide-related hemorrhagic cystitis is a principal context described in medicine references; other uses require their own specialist justification. Selection and administration depend on the companion drug, route and care plan. Clinical teams monitor urinary symptoms and other treatment-related risks. This entry intentionally omits schedules, conversion methods and chemotherapy instructions, because an ingredient catalogue cannot substitute for a verified institutional protocol and authorized product information.
Important safety considerations
Allergic and severe skin reactions can occur, including symptoms that need emergency care. Rash, facial swelling, breathing difficulty or a marked systemic reaction should be reported immediately. Blood in the urine or urinary symptoms require assessment despite mesna use. Nausea, headache and gastrointestinal symptoms may occur but can be difficult to distinguish from accompanying treatment effects. Relevant assay interference and interactions should be checked in the exact label.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The source specifies an injectable solution in ampoules of more than one size. The concentration, total amount per container, excipients and compatibility with the companion treatment must be verified separately. Oral mesna is not represented by this entry.
Professional preparation must follow the authorized label and local aseptic procedures. Confirm the correct container, concentration, route and expiry before use. Storage, transport, dilution compatibility and any period after opening or reconstitution require product-specific evidence; this page does not establish them.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Confirm the linked cytotoxic protocol, uroprotection requirements, allergy history, urinary monitoring and formulation. Supply and use require specialist pharmacy and clinical oversight.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Mesna
- Dosage form / presentation
- Injection
- Catalogue strength
- 100 mg/mL
- Catalogue pack
- Ampoule 4 mL / 10 mL
- Portfolio category
- Oncology Supportive Care
Layer 02
Unresolved product-specific fields
- The catalogue establishes an injectable mesna record at 100 mg/mL with 4 mL and 10 mL ampoule presentations. It does not establish authorised route, dilution, compatibility, timing with another medicine or administration protocol.
- The concentration and container volumes must remain controlled source fields; no unlisted total-content SKU, interchangeability or oral presentation is created from them.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- MedlinePlus: Mesna Injectiongovernment-hosted medicine monograph
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Sterile product specification confirming exact active chemical form, concentration or vial content, container/fill, authorised route(s), excipients/preservatives and preparation/compatibility controls.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-166, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-166.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.